Soleno Therapeutics (SLNO) Notes Payables (2015)

Soleno Therapeutics (SLNO) posted quarterly Notes Payables of $865000.0 for Q4 2015, down 77.54% quarter-over-quarter from $3.9 million in Q3 2015.

Soleno Therapeutics (SLNO) Notes Payables (2015) Analysis & Trends

Soleno Therapeutics (SLNO) has reported Notes Payables for 1 consecutive years, with $865000.0 the latest figure, recorded in Q4 2015.

In Q4 2015, Notes Payables changed N/A year-over-year to $865000.0; the TTM figure through Dec 2015 stood at $865000.0 (changed N/A YoY), while the FY2015 annual figure was $865000.0, changed N/A from the prior year.
Notes Payables retreated to $865000.0 in Q4 2015 per SLNO's latest filing, from $3.9 million in the prior quarter.
Across five years, Notes Payables topped out at $11.0 million in Q2 2015 and bottomed at $865000.0 in Q4 2015.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn
10	Soleno Therapeutics	2.74 Bn	2.49 Bn	93.41 Mn

Download Data